Sampling Human

Sampling Human

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.2M

Overview

Sampling Human is a private, early-stage diagnostics company pioneering single-cell analysis technologies. While the company's specific platform and pipeline are not detailed on its public homepage, its mission statement and association with high-profile scientific advisors suggest a focus on translating single-cell research into clinical tools. The company is pre-revenue and in a pre-clinical or early development stage, building its scientific foundation and leadership team.

Oncology

Technology Platform

Focused on single-cell precision analysis, likely for diagnostic applications. Specific platform details (e.g., sequencing, imaging, microfluidics) are not disclosed, but the mission and advisor expertise suggest a platform to analyze individual cells from liquid or tissue biopsies for clinical decision-making.

Funding History

1
Total raised:$4.2M
Seed$4.2M

Opportunities

The growing demand for precision medicine and non-invasive diagnostics creates a large market for single-cell liquid biopsy tools.
Successfully developing a clinically validated platform could position the company in high-value niches like early cancer detection, therapy selection, and minimal residual disease monitoring.

Risk Factors

The company faces significant technical risks in developing a robust, cost-effective clinical-grade single-cell platform.
It also operates in a highly competitive landscape against well-established players in single-cell analysis and liquid biopsy, with substantial challenges in clinical validation, commercialization, and payer reimbursement ahead.

Competitive Landscape

Sampling Human competes in the crowded and rapidly evolving single-cell analysis and liquid biopsy markets. Key competitors include platform technology companies like 10x Genomics and Mission Bio, as well as diagnostic firms like Guardant Health, Freenome, and Epic Sciences. Differentiation will require demonstrating superior clinical utility, workflow advantages, or unique biological insights.